Seonglae Cho호흡기세포융합바이러스
In a world first, RSV vaccine wins FDA approval for adults 60 and up
It's an achievement decades in the making, and more vaccines are in the pipeline.
https://arstechnica.com/science/2023/05/in-a-world-first-rsv-vaccines-wins-fda-approval-for-adults-60-and-up/
Why Pfizer’s RSV vaccine success is a big deal, decades in the making
Research on RSV vaccines dragged after a trial in the '60s went tragically wrong.
https://arstechnica.com/science/2022/11/why-pfizers-rsv-vaccine-success-is-a-big-deal-decades-in-the-making
Moderna's mRNA RSV vaccine delivers impressive Phase 3 trial results
Biotechnology company Moderna has announced promising results from its massive Phase 3 trial testing an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The data indicates the vaccine is nearly 84% effective at preventing moderate disease and the company expects to file for US...
https://newatlas.com/medical/moderna-mrna-rsv-vaccine-phase-3-trial-results
